SAN FRANCISCO, Dec. 19 - Xenon Genetics said on Wednesday that it had discovered a gene related to epilepsy and one that is associated with iron metabolism regulation.
The epilepsy gene was found through genetic analysis of families with a form of epilepsy called idiopathic generalized epilepsy. The finding was then validated clinically in humans, according to the Vancouver, B.C.-based company.
The second gene was identified through an animal model and validated as an iron metabolism regulator in humans.
Xenon said both genes were found to be drug targets for possible therapies for treating iron disorders and epilepsy.
"With these discoveries, Xenon's portfolio of validated genes associated with important biological pathways and human disease now stands at 13," Frank Holler, CEO of Xenon, said in a statement. "This growing pipeline of new genes and drug targets provides an excellent springboard from which we can identify and develop new genetically derived drugs."